AN2 Therapeutics, Inc. (ANTX) Insider Trading Disclosures
AN2 Therapeutics, Inc. (ANTX) is a publicly traded company on the Nasdaq, categorized under SIC 2834 (Pharmaceutical Preparations). Access real-time SEC filings, 10-K annual reports, 10-Q quarterlies, 8-K current reports, PCAOB auditor history, and executive compensation disclosures.
Ticker: ANTX
CIK: 1880438
Exchange: Nasdaq
SIC 2834: Pharmaceutical Preparations
Fiscal Year End: 12/31
State: DE
Independent PCAOB Auditor
Explore PCAOB Audit Intelligence →
Audit Firm
PricewaterhouseCoopers LLP
Auditor SinceSince 12/31/2021 12:00:00 AM
Lead Engagement PartnerChristopher Alabi
Audit LocationSan Jose, California, United States
Latest SEC EDGAR Filings
Showing 10-K, 10-Q, 8-K, Form 4, and other SEC submissions| Form | Filing Date | Reporting Period | Description | Accession Number | Actions |
|---|---|---|---|---|---|
| 4 | 2026-10-13 | 2026-10-12 | 4 | 0001193125-26-420643 | View SEC Doc Filr Page |
| 4 | 2026-10-13 | 2026-10-12 | 4 | 0001193125-26-420641 | View SEC Doc Filr Page |
| 4 | 2026-10-13 | 2026-10-12 | 4 | 0001193125-26-420639 | View SEC Doc Filr Page |
| 4 | 2026-09-16 | 2026-09-15 | 4 | 0001193125-26-393274 | View SEC Doc Filr Page |
| S-8 | 2026-09-14 | — | S-8 | 0001880438-26-000002 | View SEC Doc Filr Page |
| 4 | 2026-09-11 | 2026-09-09 | 4 | 0001193125-26-389545 | View SEC Doc Filr Page |
| 4 | 2026-09-08 | 2026-09-03 | 4 | 0001193125-26-385511 | View SEC Doc Filr Page |
| 4 | 2026-09-04 | 2026-09-01 | 4 | 0001193125-26-383697 | View SEC Doc Filr Page |
| 4 | 2026-09-02 | 2026-09-01 | 4 | 0001193125-26-380595 | View SEC Doc Filr Page |
| 3 | 2026-08-27 | 2026-08-24 | 3 | 0001193125-26-370943 | View SEC Doc Filr Page |
| 4 | 2026-08-19 | 2026-08-17 | 4 | 0001193125-26-357225 | View SEC Doc Filr Page |
| 144 | 2026-08-17 | — | 144 Filing | 0001972481-26-000263 | View SEC Doc Filr Page |
| 4 | 2026-08-14 | 2026-08-14 | 4 | 0001193125-26-351801 | View SEC Doc Filr Page |
| 10-Q | 2026-08-11 | 2026-06-30 | 10-Q | 0001193125-26-344569 | View SEC Doc Filr Page |
| 8-K | 2026-08-11 | 2026-08-11 | 8-K | 0001193125-26-344549 | View SEC Doc Filr Page |
| 4 | 2026-07-10 | 2026-07-10 | 4 | 0001193125-26-301167 | View SEC Doc Filr Page |
| 4 | 2026-07-10 | 2026-07-10 | 4 | 0001193125-26-301166 | View SEC Doc Filr Page |
| 4 | 2026-07-10 | 2026-07-10 | 4 | 0001193125-26-301165 | View SEC Doc Filr Page |
| 4 | 2026-07-10 | 2026-07-08 | 4 | 0001193125-26-301092 | View SEC Doc Filr Page |
| 8-K | 2026-06-09 | 2026-06-03 | 8-K | 0001193125-26-262264 | View SEC Doc Filr Page |
| 8-K | 2026-06-04 | 2026-06-04 | 8-K | 0001193125-26-257430 | View SEC Doc Filr Page |
| 4 | 2026-06-02 | 2026-05-29 | 4 | 0001193125-26-253622 | View SEC Doc Filr Page |
| SCHEDULE 13G/A | 2026-05-15 | — | SCHEDULE 13G/A Filing | 0002073679-26-000066 | View SEC Doc Filr Page |
| 10-Q | 2026-05-11 | 2026-03-31 | 10-Q | 0001193125-26-216755 | View SEC Doc Filr Page |
| 8-K | 2026-05-11 | 2026-05-11 | 8-K | 0001193125-26-216752 | View SEC Doc Filr Page |